JP7438757B2 - 治療用途のためのヒトｃペプチドとヒトエラスチン受容体との相互作用のペプチドモジュレーター - Google Patents

治療用途のためのヒトｃペプチドとヒトエラスチン受容体との相互作用のペプチドモジュレーター Download PDF

Info

Publication number
JP7438757B2
JP7438757B2 JP2019563680A JP2019563680A JP7438757B2 JP 7438757 B2 JP7438757 B2 JP 7438757B2 JP 2019563680 A JP2019563680 A JP 2019563680A JP 2019563680 A JP2019563680 A JP 2019563680A JP 7438757 B2 JP7438757 B2 JP 7438757B2
Authority
JP
Japan
Prior art keywords
peptide
seq
human
peptides
elastin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019563680A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020507623A5 (https=
JP2020507623A (ja
Inventor
ベンスフォールト，ヘルト
Original Assignee
バイオテンプト・ベー・フェー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオテンプト・ベー・フェー filed Critical バイオテンプト・ベー・フェー
Publication of JP2020507623A publication Critical patent/JP2020507623A/ja
Publication of JP2020507623A5 publication Critical patent/JP2020507623A5/ja
Priority to JP2024019238A priority Critical patent/JP2024056838A/ja
Application granted granted Critical
Publication of JP7438757B2 publication Critical patent/JP7438757B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/62—Insulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019563680A 2017-02-06 2018-02-05 治療用途のためのヒトｃペプチドとヒトエラスチン受容体との相互作用のペプチドモジュレーター Active JP7438757B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024019238A JP2024056838A (ja) 2017-02-06 2024-02-13 治療用途のためのヒトｃペプチドとヒトエラスチン受容体との相互作用のペプチドモジュレーター

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17154889 2017-02-06
EP17154889.4 2017-02-06
PCT/EP2018/052822 WO2018141969A1 (en) 2017-02-06 2018-02-05 Peptide modulators of the interaction between human c-peptide and human elastin receptor for therapeutic use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024019238A Division JP2024056838A (ja) 2017-02-06 2024-02-13 治療用途のためのヒトｃペプチドとヒトエラスチン受容体との相互作用のペプチドモジュレーター

Publications (3)

Publication Number Publication Date
JP2020507623A JP2020507623A (ja) 2020-03-12
JP2020507623A5 JP2020507623A5 (https=) 2021-03-04
JP7438757B2 true JP7438757B2 (ja) 2024-02-27

Family

ID=57995050

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019563680A Active JP7438757B2 (ja) 2017-02-06 2018-02-05 治療用途のためのヒトｃペプチドとヒトエラスチン受容体との相互作用のペプチドモジュレーター
JP2024019238A Pending JP2024056838A (ja) 2017-02-06 2024-02-13 治療用途のためのヒトｃペプチドとヒトエラスチン受容体との相互作用のペプチドモジュレーター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024019238A Pending JP2024056838A (ja) 2017-02-06 2024-02-13 治療用途のためのヒトｃペプチドとヒトエラスチン受容体との相互作用のペプチドモジュレーター

Country Status (8)

Country Link
US (4) US20200087374A1 (https=)
EP (3) EP3577462B1 (https=)
JP (2) JP7438757B2 (https=)
AU (2) AU2018216033B2 (https=)
CA (2) CA3051293A1 (https=)
ES (1) ES2927977T3 (https=)
SG (2) SG11201906943VA (https=)
WO (2) WO2018141970A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6982395B2 (ja) * 2017-03-16 2021-12-17 三洋化成工業株式会社 インターロイキン１０の産生量増加剤
WO2019104391A1 (en) * 2017-12-01 2019-06-06 St Vincent's Institute Of Medical Research Type 1 diabetes treatment
CA3149581A1 (en) * 2019-08-30 2021-03-04 Gert Wensvoort Q-er peptide
JP6895148B1 (ja) * 2020-03-31 2021-06-30 クラシエホールディングス株式会社 冷え保有者における冷えの原因が、腎機能低下、水分代謝異常又は副腎疲労にあることを判定する判定用マーカー、冷え保有者における冷えの原因が、腎機能低下、水分代謝異常又は副腎疲労にあることを判定する判定方法、及び冷え保有者における冷えの原因が、腎機能低下、水分代謝異常又は副腎疲労にあることを判定するための判定用キット
CN117106029A (zh) * 2020-06-08 2023-11-24 深圳市图微安创科技开发有限公司 靶向于纤连蛋白衍生肽的抑制剂多肽化合物及其用途
AU2021356578A1 (en) * 2020-10-08 2023-05-11 Dr. Mary Morris & Associates, Llc Methods and compositions for the treatment and prevention of type 1 diabetes
CN112345770A (zh) * 2020-11-06 2021-02-09 苏州大学附属第一医院 弹性蛋白降解肽作为腹膜透析患者血管钙化标志物的应用
KR102718109B1 (ko) * 2021-10-01 2024-10-17 (주)케어젠 탈모 방지 또는 발모 촉진 활성을 갖는 펩타이드와 이의 용도
JP2024537244A (ja) * 2021-10-05 2024-10-10 バイオテンプト ベー．フェー 好ましくは血糖コントロールと組み合わせた、血管新生コントロール
AU2023308137A1 (en) 2022-07-12 2025-01-30 Biotempt B.V. Treating conditions with hypoglycemia associated with hyperinsulinemia.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118638A1 (en) 2004-06-01 2005-12-15 Creative Peptides Sweden Ab Degradation-resistant analogues of pro-insulin c-peptide
US20070082842A1 (en) 2003-10-13 2007-04-12 Karin Ekberg Therapeutic applications for c-peptide
JP2007217422A (ja) 2001-03-29 2007-08-30 Univ Of Chicago ガストロカインおよびインヒビターによる、胃腸組織の増殖および修復の調節
WO2015021924A1 (zh) 2013-08-15 2015-02-19 上海市第一人民医院 预防和治疗炎症的小分子多肽及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE520392C2 (sv) 1996-09-27 2003-07-01 Creative Peptides Sweden Ab C Specifika peptider för behandling av diabetes mellitus
EP1578352A2 (en) * 2002-03-27 2005-09-28 University of Utah Research Foundation Elastin prevents occlusion of body vessels by vascular smooth muscle cells
GB0218970D0 (en) 2002-08-14 2002-09-25 Creative Peptides Sweden Ab Fragments of Insulin c-peptide
WO2008118387A2 (en) * 2007-03-23 2008-10-02 Wayne State University Erythrocyte atp-release modulators
CN102597775A (zh) * 2009-09-25 2012-07-18 佐马技术有限公司 筛选方法
JP2015507193A (ja) * 2012-02-01 2015-03-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性結合物の結合パートナーを検出するための方法
EP2626704B1 (en) * 2012-02-08 2015-11-18 Mehmet Ali Soylemez Diagnosis of pancreatic diabetes in patients with normal blood leucocyte counts using procalcitonin
EP2836841B1 (en) * 2012-04-12 2022-01-05 B.R.A.H.M.S GmbH Prognosis of adverse events in patients with suspected chronic heart failure
WO2014028776A1 (en) * 2012-08-15 2014-02-20 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
CA2897327A1 (en) * 2013-01-08 2014-07-17 Sphingotec Gmbh Fasting levels of growth hormone as a predictive marker of cardiovascular risk
WO2014145836A1 (en) * 2013-03-15 2014-09-18 Health Diagnostic Laboratory, Inc. Method of generating an index score for mbl deficiency to predict cardiodiabetes risk
WO2015140317A1 (en) * 2014-03-21 2015-09-24 Sanofi New markers for the assessment of the risk for development of a cardiovascular disorder

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007217422A (ja) 2001-03-29 2007-08-30 Univ Of Chicago ガストロカインおよびインヒビターによる、胃腸組織の増殖および修復の調節
US20070082842A1 (en) 2003-10-13 2007-04-12 Karin Ekberg Therapeutic applications for c-peptide
WO2005118638A1 (en) 2004-06-01 2005-12-15 Creative Peptides Sweden Ab Degradation-resistant analogues of pro-insulin c-peptide
WO2015021924A1 (zh) 2013-08-15 2015-02-19 上海市第一人民医院 预防和治疗炎症的小分子多肽及其应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DIABETES，2013年，Vol. 62, No. 11，p. 3807-3816
DOYLE, Jamie R. et al.，The Journal of Biological Chemistry，2014年，vol. 289, no. 19，p. 13385-13396
Journal of Cell Science，2005年，Vol. 118, No. 2，p. 343-356
PIAO, Wenji et al.，The Journal of Immunology，2013年，vol. 190, no. 5，p. 2263-2272

Also Published As

Publication number Publication date
EP3577462B1 (en) 2024-04-17
US20220009988A1 (en) 2022-01-13
AU2018215245B2 (en) 2024-07-11
CA3051293A1 (en) 2018-08-09
AU2018215245A1 (en) 2019-07-25
CA3049738A1 (en) 2018-08-09
EP4421088A3 (en) 2024-12-04
EP3577462A1 (en) 2019-12-11
WO2018141970A1 (en) 2018-08-09
AU2018216033A1 (en) 2019-08-15
WO2018141969A1 (en) 2018-08-09
ES2927977T3 (es) 2022-11-14
JP2024056838A (ja) 2024-04-23
US20200087374A1 (en) 2020-03-19
JP2020507623A (ja) 2020-03-12
US20250123275A1 (en) 2025-04-17
EP4421088A2 (en) 2024-08-28
SG11201906943VA (en) 2019-08-27
EP3570875A1 (en) 2019-11-27
SG11201906939XA (en) 2019-08-27
EP3577462C0 (en) 2024-04-17
AU2018216033B2 (en) 2021-10-07
US20240027431A1 (en) 2024-01-25
EP3570875B1 (en) 2022-07-06

Similar Documents

Publication Publication Date Title
JP7438757B2 (ja) 治療用途のためのヒトｃペプチドとヒトエラスチン受容体との相互作用のペプチドモジュレーター
KR102351313B1 (ko) Gip/glp1 공효능제 화합물
RS66110B1 (sr) Postupak upotrebe gip/glp1 koagonista za dijabetes
JP7788376B2 (ja) 最適化されたｇｉｐペプチド類縁体
KR20220109384A (ko) Q-er 펩타이드
AU2019386379B2 (en) DPEP-1 binding agents and methods of use
EP2252314B1 (en) Leptin agonist and methods of use
RU2662973C2 (ru) Пептидомиметики
US9109041B2 (en) Analog compounds of analgesic peptides derived from the venom of crotalus durissus terrificus snakes, their uses, compositions, methods of preparation and purification
US20090197800A1 (en) Insulin Receptor Binding Peptides with Non-Insulin Gene Activation Profiles and Uses Thereof
Korokina Studying the possibilities of pharmacological correction of hypoxia-induced pulmonary hypertension using a phenolic compound with a laboratory cypher KUD975
CN119569824A (zh) 作为神经保护剂的药用化合物及其应用
HK1162541B (en) Neurotensin conjugate and uses thereof
HK1162541A (en) Neurotensin conjugate and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220629

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230627

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240116

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240214

R150 Certificate of patent or registration of utility model

Ref document number: 7438757

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150